AveXis Inc is a United States-based clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate in Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. AVXS-101 is designed to deliver a fully functional human survival motor neuron gene into the nuclei of motor neurons that then generates an increase in survival motor neuron protein levels. The company believes this will result in improved motor neuron function and patient outcomes.
Quote | AveXis Inc. (NASDAQ:AVXS)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $217.83 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | AveXis Inc. (NASDAQ:AVXS)
Message Board Posts | AveXis Inc. (NASDAQ:AVXS)
Subject | By | Source | When |
---|---|---|---|
AVXS - AveXis Enters Agreement to be Acquired | PennyStock Alert | investorshub | 09/16/2019 12:44:11 PM |
I am curious what fellow $AVXS investors are | Barlizzy | investorshub | 04/24/2018 7:53:46 PM |
We have until May 9 to take the | Barlizzy | investorshub | 04/24/2018 7:51:51 PM |
when this will come back to ground = | bwrbad | investorshub | 04/16/2018 2:14:27 PM |
$AVXS - AveXis Enters Agreement to be Acquired | MinnieM | investorshub | 04/09/2018 6:01:23 PM |
News, Short Squeeze, Breakout and More Instantly...